Shankar Abhishek, Patil Jaineet, Sethi Niharika, Chakraborty Abhijit, Bharati Sachidanand Jee, Mandrelle Kavita, Luther Anil, Bhandari Ruchir, Rath Goura Kishor
Department of Preventive Oncology, Dr B.R.Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India. Email:
Asian Pac J Cancer Prev. 2019 Feb 26;20(2):383-389. doi: 10.31557/APJCP.2019.20.2.383.
Background: Carcinoma cervix is the second most common type of cancer in the world. With the increasing proportion of women surviving carcinoma of the cervix, quality of life has been an important clinical issue. Since there are very few studies from India, this study is to assess urinary dysfunction issues in patients of carcinoma cervix treated with multimodality therapy using the LENT SOMA scores. Methods: The study was prospective and patients treated between 1995 - 2007 on follow up were included in this study after ethical clearance. A total of 85 patients were accrued comprising 6 stage IB, 6 stage II A, 25 stage II B, 2 stage IIIA, 45 stage III B and 1 stage IV A disease. Sixty-six patients were treated with radiotherapy in which 46 patients received chemoradiotherapy and 19 had surgery prior to post-operative radiotherapy. The mean age was 47.81 years with a range of 25-68 years. Completion of LENT SOMA scale and Statistical analysis was done. Results: Mean score for BU (Bladder/Urethra) was highest (0.0758) in fifth year of treatment whereas UK (Ureter/Kidney score was highest (0.0408) after 4 years. Bladder score was more in 60-69 years of age and in stage IIIB patients of cervical cancers. Bladder morbidity was more in patients who received chemoradiotherapy and in patients who received radiotherapy with boost where Bladder and Urethra morbidity was more in patients who were treated with Extended Field radiation. Conclusions: The LENT SOMA system was acceptable and feasible to use and gave us an insight into the morbidity in our patients and to develop effective management plans to reduce the post treatment symptoms and improve quality of life.
宫颈癌是全球第二常见的癌症类型。随着宫颈癌存活女性比例的增加,生活质量已成为一个重要的临床问题。由于来自印度的相关研究非常少,本研究旨在使用LENT SOMA评分评估接受多模式治疗的宫颈癌患者的泌尿功能障碍问题。
本研究为前瞻性研究,经伦理批准后,纳入1995年至2007年期间接受治疗并进行随访的患者。共纳入85例患者,包括6例IB期、6例II A期、25例II B期、2例IIIA期、45例IIIB期和1例IVA期疾病患者。66例患者接受了放射治疗,其中46例接受了放化疗,19例在术后放疗前接受了手术。平均年龄为47.81岁,范围在25至68岁之间。完成了LENT SOMA量表并进行了统计分析。
治疗第五年时,膀胱/尿道(BU)的平均评分最高(0.0758),而输尿管/肾脏(UK)评分在4年后最高(0.0408)。60至69岁年龄段以及宫颈癌IIIB期患者的膀胱评分更高。接受放化疗的患者以及接受加量放疗的患者膀胱发病率更高,其中接受扩大野放疗的患者膀胱和尿道发病率更高。
LENT SOMA系统使用起来是可接受且可行的,它让我们了解了患者的发病率,并有助于制定有效的管理计划以减轻治疗后症状并提高生活质量。